Archived: Buprenorphine transdermal patches (BuTrans)

Advice

Following a full submission

Buprenorphine transdermal patch (BuTrans) is not recommended for use within NHS Scotland for the treatment of severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics. There was a lack of evidence of comparative efficacy with a clinically relevant treatment for chronic pain available in the UK.

The economic case has not been demonstrated. The licence holder has indicated their decision to resubmit.